AU2013339057B2 - Agent for preventing or improving decline in brain function - Google Patents

Agent for preventing or improving decline in brain function Download PDF

Info

Publication number
AU2013339057B2
AU2013339057B2 AU2013339057A AU2013339057A AU2013339057B2 AU 2013339057 B2 AU2013339057 B2 AU 2013339057B2 AU 2013339057 A AU2013339057 A AU 2013339057A AU 2013339057 A AU2013339057 A AU 2013339057A AU 2013339057 B2 AU2013339057 B2 AU 2013339057B2
Authority
AU
Australia
Prior art keywords
group
salt
decreased
glutathione
citrulline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013339057A
Other languages
English (en)
Other versions
AU2013339057A1 (en
Inventor
Kohji FUKUNAGA
Takahiro Hara
Kota KUMAGAI
Masahiko Morita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Hakko Bio Co Ltd
Original Assignee
Kyowa Hakko Bio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Bio Co Ltd filed Critical Kyowa Hakko Bio Co Ltd
Publication of AU2013339057A1 publication Critical patent/AU2013339057A1/en
Application granted granted Critical
Publication of AU2013339057B2 publication Critical patent/AU2013339057B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013339057A 2012-10-30 2013-10-30 Agent for preventing or improving decline in brain function Active AU2013339057B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012-238541 2012-10-30
JP2012238541 2012-10-30
PCT/JP2013/080052 WO2014069666A1 (en) 2012-10-30 2013-10-30 Agent for preventing or improving decline in brain function

Publications (2)

Publication Number Publication Date
AU2013339057A1 AU2013339057A1 (en) 2015-04-30
AU2013339057B2 true AU2013339057B2 (en) 2018-08-30

Family

ID=50627558

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013339057A Active AU2013339057B2 (en) 2012-10-30 2013-10-30 Agent for preventing or improving decline in brain function

Country Status (8)

Country Link
US (1) US10369186B2 (enExample)
EP (1) EP2914257B1 (enExample)
JP (1) JP6170166B2 (enExample)
AU (1) AU2013339057B2 (enExample)
CA (1) CA2888791C (enExample)
ES (1) ES2728471T3 (enExample)
NZ (1) NZ706862A (enExample)
WO (1) WO2014069666A1 (enExample)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3482025A (en) * 1964-09-28 1969-12-02 Yamanouchi Pharma Co Ltd Glutathione-amino acid compositions,and glutathione-basic amino acid salts
US20060046982A1 (en) * 2004-08-26 2006-03-02 Waugh William H Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease
JP2006273789A (ja) * 2005-03-30 2006-10-12 Pias Arise Kk セラミダーゼ阻害剤、及びその阻害剤を含む皮膚外用剤、化粧料、医薬部外品
WO2009096505A1 (ja) * 2008-01-30 2009-08-06 Kyowa Hakko Bio Co., Ltd. 注意集中力向上剤
WO2009099132A1 (ja) * 2008-02-05 2009-08-13 Kyowa Hakko Bio Co., Ltd. グルタチオンの保存安定性向上方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010056068A1 (en) 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
AU5939901A (en) * 2000-10-27 2002-05-06 Nitromed Inc Methods of treating vascular diseases characterized by nitric oxide insufficiency
AU2002333018B2 (en) * 2001-09-27 2006-08-31 The Mental Health Research Institute Of Victoria Modulation of physiological processes and agents useful for same
US20090047340A1 (en) * 2006-03-29 2009-02-19 Guilford F Timothy Liposomal reduced glutathione and 1-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis
US8597640B2 (en) 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
AU2008347177B2 (en) * 2008-01-04 2014-04-17 Société des Produits Nestlé S.A. Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions
JP2010126462A (ja) * 2008-11-26 2010-06-10 Mitsubishi Gas Chemical Co Inc 脳機能改善用組成物および該組成物を含有する機能性食品

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3482025A (en) * 1964-09-28 1969-12-02 Yamanouchi Pharma Co Ltd Glutathione-amino acid compositions,and glutathione-basic amino acid salts
US20060046982A1 (en) * 2004-08-26 2006-03-02 Waugh William H Orthomolecular medical use of L-citrulline for capillary endothelial protection and adjacent cell protection in neurodegenerative disease
JP2006273789A (ja) * 2005-03-30 2006-10-12 Pias Arise Kk セラミダーゼ阻害剤、及びその阻害剤を含む皮膚外用剤、化粧料、医薬部外品
WO2009096505A1 (ja) * 2008-01-30 2009-08-06 Kyowa Hakko Bio Co., Ltd. 注意集中力向上剤
WO2009099132A1 (ja) * 2008-02-05 2009-08-13 Kyowa Hakko Bio Co., Ltd. グルタチオンの保存安定性向上方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CRUZ R ET AL, REVISTA DE NEUROLOGIA, VIGUERA EDITORES, ES, (20030501), vol. 36, no. 9, ISSN 0210-0010, pages 877 - 886 *

Also Published As

Publication number Publication date
JP2015535240A (ja) 2015-12-10
EP2914257A1 (en) 2015-09-09
ES2728471T3 (es) 2019-10-24
CA2888791A1 (en) 2014-05-08
US10369186B2 (en) 2019-08-06
NZ706862A (en) 2019-03-29
JP6170166B2 (ja) 2017-07-26
AU2013339057A1 (en) 2015-04-30
EP2914257B1 (en) 2019-04-03
EP2914257A4 (en) 2016-07-27
US20150265670A1 (en) 2015-09-24
CA2888791C (en) 2021-07-27
WO2014069666A1 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
US11738037B2 (en) Agent for preventing or improving decline in brain function
US12465584B2 (en) Agent for elevating nitric oxide concentration
JP6193229B2 (ja) 血管内皮機能低下の予防または改善剤
CN101460159B (zh) 疲劳缓解剂
US20160296586A1 (en) Agent for preventing or ameliorating vascular endothelial malfunction
JP5931325B2 (ja) 注意集中力向上剤
US10369186B2 (en) Method of treating decline in brain function comprising coadministration of citrulline and glutathione
US20170042962A1 (en) Agent for preventing or ameliorating vascular endothelial malfunction
JPWO2015199203A1 (ja) 眼の疲れ改善剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)